Results 71 to 80 of about 32,786 (220)

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis [PDF]

Blood, 2012
Abstract Immunoglobulin light-chain (AL) amyloidosis is a rare, incurable plasma cell disorder. Its therapy has benefited immensely from the expanding drug armamentarium available for multiple myeloma. Pomalidomide in combination with weekly dexamethasone (Pom/dex) is active among patients with relapsed myeloma.
Angela, Dispenzieri, Francis, Buadi, Kristina, Laumann, Betsy, LaPlant, Suzanne R, Hayman, Shaji K, Kumar, David, Dingli, Steven R, Zeldenrust, Joseph R, Mikhael, Robert, Hall, S Vincent, Rajkumar, Craig, Reeder, Rafael, Fonseca, P Lief, Bergsagel, A Keith, Stewart, Vivek, Roy, Thomas E, Witzig, John A, Lust, Stephen J, Russell, Morie A, Gertz, Martha Q, Lacy   +20 more
openaire   +2 more sources

Molecular pathogenesis and progression of light chain amyloidosis [PDF]

, 2022
Light chain amyloidosis is a malignant plasma cell disease characterized by the production and secretion of immunoglobulin light chains, aggregating as amyloid and causing end organ damage, most frequently in heart and kidney.
Beck, Susanne Monika
core   +1 more source

Cardiac Amyloidosis: Clinical Features, Pathogenesis, Diagnosis, and Treatment [PDF]

Türk Patoloji Dergisi
Cardiac amyloidosis is a type of amyloidosis that deserves special attention as organ involvement significantly worsens the prognosis. Cardiac amyloidosis can be grouped under three main headings: immunoglobulin light chain (AL) amyloidosis that is ...
Asuman ARGON, Deniz NART, Funda YILMAZ BARBET   +2 more
doaj   +1 more source

Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis

ESC Heart Failure, Volume 12, Issue 2, Page 809-818, April 2025.
Abstract Aims This study aimed to evaluate the change of the main electrocardiographic (ECG) characteristics and their prognostic role across the main subtypes of cardiac amyloidosis [light‐chain amyloidosis (AL) and hereditary (ATTRv) and wild‐type transthyretin amyloidosis (ATTRwt)].
Alessia Argirò, Mattia Zampieri, Carlotta Mazzoni, Carlo Fumagalli, Michela Baccini, Alessandra Mattei, Alberto Cipriani, Laura De Michieli, Aldostefano Porcari, Gianfranco Sinagra, Marco Merlo, Giacomo Tini, Beatrice Musumeci, Domitilla Russo, Pier Filippo Vianello, Marco Canepa, Roberto Licordari, Gianluca di Bella, Claudio Rapezzi, Federico Perfetto, Francesco Cappelli   +20 more
wiley   +1 more source

Light-chain amyloidosis with dysphagia as the main symptom: a case report

Journal of Medical Case Reports
Background Immunoglobulin light-chain amyloidosis is a relatively rare condition with a worldwide incidence of 5.1–12.8 cases per million person-years (Baker, 2022).
Maomao Ai, Tao Lin, Ruoyu Guo, Haiyao Zheng, Haiyan Deng, Feng Yu   +5 more
doaj   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Clinical Outcome of Immunoglobulin Light Chain Amyloidosis Affecting the Kidney [PDF]

Blood, 2008
Abstract Introduction: The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy have not been well described in this patient group Patients: 145 patients with AL who participated
Morie A, Gertz, Nelson, Leung, Martha Q, Lacy, Angela, Dispenzieri, Steven R, Zeldenrust, Suzanne R, Hayman, Francis K, Buadi, David, Dingli, Philip R, Greipp, Shaji K, Kumar, John A, Lust, S Vincent, Rajkumar, Stephen J, Russell, Thomas E, Witzig   +13 more
openaire   +2 more sources

Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis. [PDF]

PLoS ONE, 2007
BACKGROUND: Amyloid is insoluble aggregated proteins deposited in the extra cellular space. About 25 different proteins are known to form amyloid in vivo and are associated with severe diseases such as Alzheimer's disease, prion diseases and type-2 ...
Stina Enqvist, Knut Sletten, Fred J Stevens, Ulf Hellman, Per Westermark   +4 more
doaj   +1 more source

Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up

British Journal of Haematology, 2021
Lenalidomide and dexamethasone (RD) is a standard treatment in relapsed/refractory immunoglobulin light chain (AL) amyloidosis (RRAL). We retrospectively investigated toxicity, efficacy and prognostic markers in 260 patients with RRAL.
M. Basset, C. Kimmich, Nicholas Schreck, J. Krzykalla, Tobias Dittrich, K. Veelken, H. Goldschmidt, A. Seckinger, D. Hose, A. Jauch, C. Müller-Tidow, A. Benner, U. Hegenbart, S. Schönland   +13 more
semanticscholar   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source